APAnsu O. Perekatt

Ansu O. Perekatt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ansu O. Perekatt has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dedifferentiation-driven oncogenic stemness promotes tumor-sustaining adaptability in the intestinal epithelium

    by Kylee Zgeib, Thompson Hui, Simon Garcia, Zahra Hashemi, Shima Nejati, Amartya Singh, Atharva Inamdar, Crystal Lim, Dahlia Matouba, Christina Li, et al.

    Intestinal tumorigenesis can occur via two distinct routes: bottom-up tumorigenesis occurs from mutations sustained in the Lgr5⁺ stem cells, whereas top-down tumorigenesis is driven by dedifferentiation of epithelial cells near the intestinal lumen. While sporadic human colon adenomas exhibit features of top-down tumorigenesis, their biological determinants remain elusive. Here, using a Smad4 loss-of-function and β-catenin gain-of-function (Smad4 LOF :β-catenin GOF ) mouse model, we demonstrate that dedifferentiation-derived oncogenic stem cells sustain tumorigenesis more effectively than endogenous mutant stem cells harboring the mutation. The dedifferentiating villi epithelial cells showed early expression of CD44 and Lgr5 , supporting oncogenic stemness. Aberrant Notch signaling in the villi epithelium was also detected at the onset of dedifferentiation, suggesting its contribution to dedifferentiation. Single-cell RNA sequencing revealed a distinct population of dedifferentiation-derived stem cells enriched for proliferative, metabolic, and mouse embryonic stem cell-like gene signatures, consistent with enhanced plasticity and tumorigenic potential. These mutant cells exhibited growth factor independence, indicating a capacity for niche-independent proliferation and metabolic adaptation to sustain tumor growth. These findings identify dedifferentiation-driven stemness, aberrant Notch activation, and metabolic plasticity as cooperative mechanisms that promote top-down intestinal tumorigenesis. This study provides insight into how oncogenic dedifferentiation contributes to tumor heterogeneity and persistence and has implications for therapeutic resistance in colorectal cancer.


  • Open Access

    Epithelial-specific loss of Smad4 alleviates the fibrotic response in an acute colitis mouse model

    by Zahra Hashemi, Thompson Hui, Alex Wu, Dahlia Matouba, Steven Zukowski, Shima Nejati, Crystal Lim, Julianna Bruzzese, Cindy Lin, Kyle Seabold, et al.

    Mucosal healing is associated with better clinical outcomes in patients with inflammatory bowel disease. But the epithelial-specific contribution to mucosal healing in vivo is poorly understood. We evaluated mucosal healing in an acute dextran sulfate sodium mouse model that shows an alleviated colitis response after epithelial-specific loss of Smad4. We find that enhanced epithelial wound healing alleviates the fibrotic response. Dextran sulfate sodium caused increased mesenchymal collagen deposition—indicative of fibrosis—within a week in the WT but not in the Smad4 KO colon. The fibrotic response correlated with decreased epithelial proliferation in the WT, whereas uninterrupted proliferation and an expanded zone of proliferation were observed in the Smad4 KO colon epithelium. Furthermore, the Smad4 KO colon showed epithelial extracellular matrix alterations that promote epithelial regeneration. Our data suggest that epithelium is a key determinant of the mucosal healing response in vivo, implicating mucosal healing as a strategy against fibrosis in inflammatory bowel disease patients.


  • Open Access

    Smad4 Loss in the Mouse Intestinal Epithelium Alleviates the Pathological Fibrotic Response to Injury in the Colon

    by Zahra Hashemi, Thompson Hui, Alex Wu, Dahlia Matouba, Steven Zukowski, Shima Nejati, Crystal Lim, Julianna Bruzzese, Kyle Seabold, Connor Mills, et al.

    Mucosal healing is associated with better clinical outcomes in patients with inflammatory bowel diseases (IBDs). Unresolved injury and inflammation, on the other hand, increases pathological fibrosis and the predisposition to cancer. Loss of Smad4, a tumor suppressor, is known to increase colitis-associated cancer in mouse models of chronic IBD. Since common biological processes are involved in both injury repair and tumor growth, we sought to investigate the effect of Smad4 loss on the response to epithelial injury. To this end, Smad4 was knocked out specifically in the intestinal epithelium and transcriptomic and morphological changes compared between wild type mice and Smad4 knock out mice after DSS-induced injury. We find that Smad4 loss alleviates pathological fibrosis and enhances mucosal repair. The transcriptomic changes specific to epithelium indicate molecular changes that affect epithelial extracellular matrix (ECM) and promote enhanced mucosal repair. These findings suggest that the biological processes that promote wound healing alleviate the pathological fibrotic response to DSS. Therefore, these mucosal repair processes could be exploited to develop therapies that promote normal wound healing and prevent fibrosis. NEW AND NOTEWORTHY: We show that transcriptomic changes due to Smad4 loss in the colonic epithelium alleviates the pathological fibrotic response to DSS in an IBD mouse model of acute inflammation. Most notably, we find that collagen deposition in the epithelial ECM, as opposed to that in the lamina propria, correlates with epithelial changes that enhance wound healing. This is the first report on a mouse model providing alleviated fibrotic response in a DSS-IBD mouse model in vivo .

  • Open Access

    In Vitro Organoid-Based Assays Reveal SMAD4 Tumor-Suppressive Mechanisms for Serrated Colorectal Cancer Invasion

    by Kevin Tong, Manisha Bandari, Jillian N. Carrick, Anastasia Zenkevich, Om A. Kothari, Eman Shamshad, Katarina Stefanik, Katherine S. Haro, Ansu O. Perekatt, Michael P. Verzi

    Colon cancer is the third most prominent cancer and second leading cause of cancer-related deaths in the United States. Up to 20% of colon cancers follow the serrated tumor pathway driven by mutations in the MAPK pathway. Loss of SMAD4 function occurs in the majority of late-stage colon cancers and is associated with aggressive cancer progression. Therefore, it is important to develop technology to accurately model and better understand the genetic mechanisms behind cancer invasion. Organoids derived from tumors found in the Smad4KO BRAFV600E/+ mouse model present multiple phenotypes characteristic of invasion both in ex vivo and in vivo systems. Smad4KO BRAFV600E/+ tumor organoids can migrate through 3D culture and infiltrate through transwell membranes. This invasive behavior can be suppressed when SMAD4 is re-expressed in the tumor organoids. RNA-Seq analysis reveals that SMAD4 expression in organoids rapidly regulates transcripts associated with extracellular matrix and secreted proteins, suggesting that the mechanisms employed by SMAD4 to inhibit invasion are associated with regulation of extracellular matrix and secretory pathways. These findings indicate new models to study SMAD4 regulation of tumor invasion and an additional layer of complexity in the tumor-suppressive function of the SMAD4/Tgfβ pathway.


  • Open Access

    Description of Supplemental Figures from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer

    by Priya S. Mathur, Jessica J. Gierut, Grace Guzman, Hui Xie, Rosa M. Xicola, Xavier Llor, Michael I. Chastkofsky, Ansu O. Perekatt, Angela L. Tyner

  • Open Access

    Figure S1 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer

    by Priya S. Mathur, Jessica J. Gierut, Grace Guzman, Hui Xie, Rosa M. Xicola, Xavier Llor, Michael I. Chastkofsky, Ansu O. Perekatt, Angela L. Tyner

    Supplemental Figure; Additional PTK6 localization and expression data

  • Open Access

    Figure S2 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer

    by Priya S. Mathur, Jessica J. Gierut, Grace Guzman, Hui Xie, Rosa M. Xicola, Xavier Llor, Michael I. Chastkofsky, Ansu O. Perekatt, Angela L. Tyner

    Supplemental Figure: Differential activation of p38 in breast and colon cancer cell lines

  • Open Access

    Figure S3 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer

    by Priya S. Mathur, Jessica J. Gierut, Grace Guzman, Hui Xie, Rosa M. Xicola, Xavier Llor, Michael I. Chastkofsky, Ansu O. Perekatt, Angela L. Tyner

    Supplemental Figure: Decreased PTK6 Expression in Tumors in Oncomine Datasets

  • 3D Culturing of Organoids from the Intestinal Villi Epithelium Undergoing Dedifferentiation

    by Christina Li, Jeel Shah, Kylee Wrath, Dahlia Matouba, Connor Mills, Kishore Punnath, Ansu Perekatt

    Clonogenicity of organoids from the intestinal epithelium is attributed to the presence of stem cells therein. The mouse small intestinal epithelium is compartmentalized into crypts and villi: the stem and proliferating cells are confined to the crypts, whereas the villi epithelium contains only differentiated cells. Hence, the normal intestinal crypts, but not the villi, can give rise to organoids in 3D cultures. The procedure described here is applicable only to villus epithelium undergoing dedifferentiation leading to stemness. The method described uses the Smad4-loss-of-function:β-catenin gain-of-function (Smad4KO:β-cateninGOF) conditional mutant mouse. The mutation causes the intestinal villi to dedifferentiate and generate stem cells in the villi. Intestinal villi undergoing dedifferentiation are scraped off the intestine using glass slides, placed in a 70 µm strainer and washed several times to filter out any loose cells or crypts prior to plating in BME-R1 matrix to determine their organoid-forming potential. Two main criteria were used to ensure that the resulting organoids were developed from the dedifferentiating villus compartment and not from the crypts: 1) microscopically evaluating the isolated villi to ensure absence of any tethered crypts, both before and after plating in the 3D matrix, and 2) monitoring the time course of organoid development from the villi. Organoid initiation from the villi occurs only two to five days after plating and appears irregularly shaped, whereas the crypt-derived organoids from the same intestinal epithelium are apparent within sixteen hours of plating and appear spherical. The limitation of the method, however, is that the number of organoids formed, and the time required for organoid initiation from the villi vary depending on the degree of dedifferentiation. Hence, depending upon the specificity of the mutation or the insult causing the dedifferentiation, the optimal stage at which villi can be harvested to assay their organoid forming potential, must be determined empirically.